---
figid: PMC7226210__cancers-12-00916-g002
figtitle: The most relevant molecular pathways and targeted agents in TNBC
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC7226210
filename: cancers-12-00916-g002.jpg
figlink: pmc/articles/PMC7226210/figure/cancers-12-00916-f002/
number: F2
caption: 'Schematic of the most relevant molecular pathways and targeted agents in
  TNBC. Tyrosine kinase receptor is activated upon binding of growth factors leading
  to activation of signaling pathways. PI3K/AKT pathway and inhibitor drugs: Phosphorylated
  PI3K activate AKT. The activation of AKT triggers downstream protein complexes mTORC
  activation that initiate gene transcription and promote cell growth. AR pathway
  is activated in LAR subtype tumors. Platinum drugs act through DNA damaging mechanism.
  PARP inhibitors induce “synthetic lethality” in BRCA deficient tumors.'
papertitle: The Landscape of Targeted Therapies in TNBC.
reftext: Elena Vagia, et al. Cancers (Basel). 2020 Apr;12(4):916.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9433166
figid_alias: PMC7226210__F2
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC7226210__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7226210__cancers-12-00916-g002.html
  '@type': Dataset
  description: 'Schematic of the most relevant molecular pathways and targeted agents
    in TNBC. Tyrosine kinase receptor is activated upon binding of growth factors
    leading to activation of signaling pathways. PI3K/AKT pathway and inhibitor drugs:
    Phosphorylated PI3K activate AKT. The activation of AKT triggers downstream protein
    complexes mTORC activation that initiate gene transcription and promote cell growth.
    AR pathway is activated in LAR subtype tumors. Platinum drugs act through DNA
    damaging mechanism. PARP inhibitors induce “synthetic lethality” in BRCA deficient
    tumors.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Hras
  - Kras
  - Rem1
  - Grb2
  - Pik3ca
  - Ecm1
  - Ppp1r13b
  - Pik3r1
  - Irs1
  - Rps6kb1
  - Zhx2
  - Eif4ebp1
  - Mtor
  - Pten
  - Pdk1
  - Pdpk1
  - Tsc2
  - Tsc1
  - Mdk
  - Akt1
  - Ephb2
  - Mapk1
  - Ar
  - Parp1
  - Brca1
  - Pt
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - KRAS
  - HRAS
  - NRAS
  - GRB2
  - CUX1
  - SART3
  - RB1
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - XYLT2
  - SOS1
  - SOS2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - IRS1
  - MTG1
  - RPS6KB1
  - MTOR
  - RPTOR
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - EIF4EBP1
  - PTEN
  - PDK1
  - PDPK1
  - TSC2
  - TSC1
  - CCL26
  - MAPKAP1
  - RICTOR
  - MLST8
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - AR
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - BRCA1
  - tyrosine
  - GDP
  - Everolimus
  - Temsirolimus
  - Pt
---
